Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators

International Journal of Experimental Pathology

Volumn 91, Issue 4, 2010, Pages 303-313

  Murphy, Gillian ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

ADAM; exosite; Metzincin; MMP; protease inhibitor

Indexed keywords

ADAM PROTEIN; MATRIX METALLOPROTEINASE;

CATALYSIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADAM PROTEINS; ANIMALS; CATALYTIC DOMAIN; DRUG DESIGN; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955060812     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2010.00736.x     Document Type: Review

References (91)

1. Apte S.S. (2009) A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J. Biol. Chem. 284, 31493 31497.
2. Askari J.A., Buckley P.A., Mould A.P., Humphries M.J. (2009) Linking integrin conformation to function. J. Cell Sci. 122, 165 170.
3. Bell J.H., Herrera A.H., Li Y., Walcheck B. (2007) Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J. Leukoc. Biol. 82, 173 176.
4. Bigg H.F., Morrison C.J., Butler G.S. et al. (2001) Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res. 61, 3610 3618.
5. Blobel C.P. (2005) ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6, 32 43.
6. Boutet P., Aguera-Gonzalez S., Atkinson S. et al. (2009) Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J. Immunol. 182, 49 53.
7. Brule S., Charnaux N., Sutton A. et al. (2006) The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16, 488 501.
8. Butler G.S., Butler M.J., Atkinson S.J. et al. (1998) The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. J. Biol. Chem 273, 871 880.
9. Butler G.S., Dean R.A., Smith D., Overall C.M. (2009) Membrane protease degradomics: proteomic identification and quantification of cell surface protease substrates. Methods Mol. Biol. 528, 159 176.
10. Chen P., Abacherli L.E., Nadler S.T., Wang Y., Li Q., Parks W.C. (2009) MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation. PLoS ONE 4, e6565.
11. Chung L., Dinakarpandian D., Yoshida N. et al. (2004) Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J. 23, 3020 3030.
12. DasGupta S., Murumkar P.R., Giridhar R., Yadav M.R. (2009) Current perspective of TACE inhibitors: a review. Bioorg. Med. Chem. 17, 444 459.
13. 1 integrin upon release from keratinocytes migrating on type I collagen. J. Biol. Chem. 276, 29368 29374.
14. Edwards D.R., Handsley M.M., Pennington C.J. (2008) The ADAM metalloproteinases. Mol. Aspects Med. 29, 258 289.
15. Endo K., Takino T., Miyamori H. et al. (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 278, 40764 40770.
16. Fanjul-Fernandez M., Folgueras A.R., Cabrera S., Lopez-Otin C. (2010) Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 1803, 3 19.
17. Folgueras A.R., Pendas A.M., Sanchez L.M., Lopez-Otin C. (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 48, 411 424.
18. Fosang A.J. Little C.B. (2008) Drug insight: aggrecanases as therapeutic targets for osteoarthritis. Nat. Clin. Pract. Rheumatol. 4, 420 427.
19. Garton K.J., Gough P.J., Raines E.W. (2006) Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J. Leukoc. Biol. 79, 1105 1116.
20. Georgiadis D. Yiotakis A. (2008) Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg. Med. Chem. 16, 8781 8794.
21. Gerg M., Kopitz C., Schaten S. et al. (2008) Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases. Mol. Cancer Res. 6, 341 351.
22. Gill S.E. Parks W.C. (2008) Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 40, 1334 1347.
23. Gomis-Rüth F.X. (2009) Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 284, 15353 15357.
24. Gonzales P.E., Solomon A., Miller A.B., Leesnitzer M.A., Sagi I., Milla M.E. (2004) Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J. Biol. Chem. 279, 31638 31645.
25. Gonzales P.E., Galli J.D., Milla M.E. (2008) Identification of key sequence determinants for the inhibitory function of the prodomain of TACE. Biochemistry 47, 9911 9919.
26. Gross J. Lapiere C.M. (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014 1022.
27. Guaiquil V., Swendeman S., Yoshida T., Chavala S., Campochiaro P.A., Blobel C.P. (2009) ADAM9 is involved in pathological retinal neovascularization. Mol. Cell. Biol. 29, 2694 2703.
28. Guaiquil V.H., Swendeman S., Zhou W. et al. (2010) ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J. Mol. Med. 88, 4247 4257.
29. Guan H.H., Goh K.S., Davamani F. et al. (2010) Structures of two elapid snake venom metalloproteases with distinct activities highlight the disulfide patterns in the D domain of ADAMalysin family proteins. J. Struct. Biol. 169, 294 303.
30. Hass M.R., Sato C., Kopan R., Zhao G. (2009) Presenilin: RIP and beyond. Semin. Cell Dev. Biol. 20, 201 210.
31. Hikita A., Yana I., Wakeyama H. et al. (2006) Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J. Biol. Chem. 281, 36846 36855.
32. Horiuchi K., Le Gall S., Schulte M. et al. (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol. Biol. Cell 18, 176 188.
33. Hotary K.B., Yana I., Sabeh F. et al. (2002) Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J. Exp. Med. 195, 295 308.
34. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480 498.
35. Itoh Y. Seiki M. (2006) MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol. 206, 1 8.
36. Iyer S., Visse R., Nagase H., Achorya K.R. (2006) Crystal structure of an active form of human MMP-1. J. Mol. Biol. 362, 78 88.
37. Janes P.W., Saha N., Barton W.A. et al. (2005) Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123, 291 304.
38. Jozic D., Bourenkov G., Lim N.H., Visse R., Nagase H., Bode W., Maskos K. (2005) X-ray structure of human pro MMP-1: new insights into procollagenase activation and collagen binding. J. Biol. Chem. 280, 9578 9585.
39. Kjeldsen L., Johnsen A.H., Sengelov H., Borregaard N. (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268, 10425 10432.
40. Lee M.H., Verma V., Maskos K. et al. (2002) Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha- converting enzyme. Biochem. J. 364, 227 234.
41. Li J., Bick P., O'Hare M.C., Skarzynski T., Lloyd L.F., Curry V.A., Clark I.M. et al. (1995) Structure of full length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked four bladed beta-propeller. Structure 3, 541 549.
42. Li Q., Park P.W., Wilson C.L., Parks W.C. (2002) Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635 646.
43. Liu C., Xu P., Lamouille S., Xu J., Derynck R. (2009) TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. Mol. Cell 35, 26 36.
44. Lopez-Otin C. Overall C.M. (2002) Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 3, 509 519.
45. Lynch C.C., Hikosaka A., Acuff H.B. et al. (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7, 485 496.
46. McCawley L.J. Matrisian L.M. (2001) Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534 540.
47. McQuibban G.A., Gong J.H., Tam E.M., McCulloch C.A., Clark-Lewis I., Overall C.M. (2000) Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202 1206.
48. Mix K.S., Sporn M.B., Brinckerhoff C.E., Eyre D., Schurman D.J. (2004) Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. Clin. Orthop. Relat. Res. 427 (Suppl. S129 S137.
49. Morgan M.R., Humphries M.J., Bass M.D. (2007) Synergistic control of cell adhesion by integrins and syndecans. Nat. Rev. Mol. Cell Biol. 8, 957 969.
50. Morrison C.J., Butler G.S., Rodriguez D., Overall C.M. (2009) Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 21, 645 653.
51. Moss M.L. Bartsch J.W. (2004) Therapeutic benefits from targeting of ADAM family members. Biochemistry 43, 7227 7235.
52. Moss M.L., Bomar M., Liu Q. et al. (2007) The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J. Biol. Chem. 282, 35712 35721.
53. Murphy G. (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 8, 929 941.
54. Murphy G. (2009) Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Semin. Cell Dev. Biol. 20, 138 145.
55. Murphy G. Nagase H. (2008) Progress in matrix metalloproteinase research. Mol. Aspects Med. 29, 290 308.
56. Murphy G., Nguyen Q., Cockett M.I. et al. (1994) Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J. Biol. Chem. 269, 6632 6636.
57. Murphy G., Murthy A., Khokha R. (2008) Clipping, shedding and RIPping keep immunity on cue. Trends Immunol. 29, 75 82.
58. Nuti E., Tuccinardi T., Rossello A. (2007) Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des. 13, 2087 2100.
59. O'Connell J.P., Willenbrock F., Docherty A.J.P., Eaton D., Murphy G. (1994) Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J. Biol. Chem. 269, 14967 14973.
60. Ogata Y., Itoh Y., Nagase H. (1995) Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J. Biol. Chem. 270, 18506 18511.
61. O'Reilly L.A., Kruse E.A., Puthalakath H. et al. (2009) MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. J. Immunol. 183, 261 269.
62. Overall C.M. Blobel C.P. (2007) In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 8, 245 257.
63. Overall C.M. Lopez-Otin C. (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657 672.
64. Porter S., Clark I.M., Kevorkian L., Edwards D.R. (2005) The ADAMTS metalloproteinases. Biochem. J. 386, 15 27.
65. Powell W.C., Fingleton B., Wilson C.L., Boothby M., Matrisian L.M. (1999) The metalloproteinase matrilysin proteolytically generates active soluble fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9, 1441 1447.
66. Pruessmeyer J. Ludwig A. (2009) The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin. Cell Dev. Biol. 20, 164 174.
67. Pruessmeyer J., Martin C., Hess F.M. et al. (2010) A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J. Biol. Chem. 285, 555 564.
68. Ra H.J. Parks W.C. (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587 596.
69. Ra H.J., Harju-Baker S., Zhang F., Linhardt R.J., Wilson C.L., Parks W.C. (2009) Control of promatrilysin (MMP7) activation and substrate-specific activity by sulfated glycosaminoglycans. J. Biol. Chem. 284, 27924 27932.
70. Reddy P., Slack J.L., Davis R. et al. (2000) Functional analysis of the domain structure of tumor necrosis factor- alpha converting enzyme. J. Biol. Chem. 275, 14608 14614.
71. Reiss K. Saftig P. (2009) The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin. Cell Dev. Biol. 20, 126 137.
72. Reiss K., Ludwig A., Saftig P. (2006) Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol. Ther. 111, 985 1006.
73. Rose-John S., Scheller J., Elson G., Jones S.A. (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80, 227 236.
74. Rosenblum G., Van den Steen P.E., Cohen S.R. et al. (2007) Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Structure 15, 1227 1236.
75. Schulte M., Reiss K., Lettau M. et al. (2007) ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 14, 1040 1049.
76. Seals D.F. Courtneidge S.A. (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17, 7 30.
77. Sela-Passwell N., Rosenblum G., Shoham T., Sagi I. (2010) Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? Biochim. Biophys. Acta 1803, 29 38.
78. Shipley J.M., Doyle G.A.R., Fliszar C.J. et al. (1996) The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. J. Biol. Chem. 271, 4335 4341.
79. Solomon A., Akabayov B., Frenkel A., Milla M.E., Sagi I. (2007) Key feature of the catalytic cycle of TNF-alpha converting enzyme involves communication between distal protein sites and the enzyme catalytic core. Proc. Natl Acad. Sci. USA 104, 4931 4936.
80. Sterchi E.E., Stocker W., Bond J.S. (2008) Meprins, membrane-bound and secreted astacin metalloproteinases. Mol. Aspects Med. 29, 309 328.
81. Su G., Blaine S.A., Qiao D., Friedl A. (2008) Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res. 68, 9558 9565.
82. Suenaga N., Mori H., Itoh Y., Seiki M. (2005) CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 24, 859 868.
83. Swendeman S., Mendelson K., Weskamp G. et al. (2008) VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ. Res. 103, 916 918.
84. Takeda S. (2008) Three-dimensional domain architecture of the ADAM family proteinases. Semin. Cell Dev. Biol. 20, 146 152.
85. Takeda S., Igarashi T., Mori H. (2007) Crystal structure of RVV-X: an example of evolutionary gain of specificity by ADAM proteinases. FEBS Lett. 581, 5859 5864.
86. Tousseyn T., Thathiah A., Jorissen E. et al. (2009) ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J. Biol. Chem. 284, 11738 11747.
87. Visse R. Nagase H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827 839.
88. Wolfe M.S. (2006) The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45, 7931 7939.
89. Yao J.S., Chen Y., Zhai W., Xu K., Young W.L., Yang G.Y. (2004) Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ. Res. 95, 364 371.
90. Yiotakis A. Dive V. (2008) Synthetic active site-directed inhibitors of metzincins: achievement and perspectives. Mol. Aspects Med. 29, 329 338.
91. Yu W.H. Woessner J.F. Jr., (2000) Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J. Biol. Chem. 275, 4183 4191.